Deniz Goren

Istanbul, 34060, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology.

Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology.

Journal: Journal of clinical medicine

Published: June 24, 2026

Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: March 26, 2026

Clinicopathological features of adult lymphoblastic lymphoma: a retrospective multicenter study from Türkiye.

Clinicopathological features of adult lymphoblastic lymphoma: a retrospective multicenter study from Türkiye.

Journal: Frontiers in oncology

Published: March 01, 2026

A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting Therapies

A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting Therapies

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: November 07, 2025

Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group.

Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group.

Journal: Journal of clinical medicine

Published: August 24, 2025

Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients.

Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients.

Journal: Cancer

Published: August 13, 2025

Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.

Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.

Journal: Annals of hematology

Published: August 13, 2025

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.

Journal: British journal of haematology

Published: January 29, 2025

A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.

A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.

Journal: Arquivos brasileiros de oftalmologia

Published: January 10, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026